UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 11, 2026 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) FORM 8-K (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 3100 Hanover Street Palo Alto, California 94304 (Address of principal execut ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT (State or Other Jurisdiction of Incorporation) 11711 N. Meridian Street Suite 300 Carmel, Indiana 46032 (Address of Principal Executive Offices) (Zip Code) Delaware 001-42272 84-1882872 (Commission File Number) (IRS Employer Identification No.) Date of Report (Date of earliest event reported): January 11, 2026 MBX Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Registrant's Telephone Numb ...

EXHIBIT 99.1 Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time) TEL AVIV, Israel, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will present its ongoing transformation and expec ...

Financial Performance - As of year-end 2025, the company has approximately $310 million in cash, including a one-time $75 million milestone from GSK due to Jemperli achieving $1 billion in worldwide net sales in November 2025[6]. - Jemperli generated $303 million in Q3 2025, reflecting a greater than 16% quarter-over-quarter growth rate, with an annualized run rate exceeding $1.2 billion[14]. - The company expects to receive over $390 million annually in Jemperli royalties at GSK's peak sales guidance of over $2.7 billion, anticipated to be achieved before 2031[14]. - Jemperli's revenue forecasts indicate a steep growth trajectory, with projected sales reaching over $2 billion by 2031[16]. Corporate Strategy - The company plans to separate into two independent publicly traded entities by Q2 2026 to maximize shareholder value[6]. - The anticipated paydown of financial obligations to Sagard is projected between Q2 2027 and Q1 2028, based on Jemperli's continued strong growth[14]. - The company anticipates minimal infrastructure and staff requirements post-separation, focusing on protecting and returning value from royalty assets[6]. - The company is focused on expanding its market presence and enhancing its product pipeline through ongoing clinical trials and research[116]. Clinical Trials and Drug Development - The company is initiating a Phase 1b clinical trial for ANB033 in Eosinophilic Esophagitis in Q1 2026, with top-line data from the Phase 1b trial in Celiac Disease expected in Q4 2026[8]. - Imsidolimab has received FDA BLA submission for generalized pustular psoriasis (GPP) in December 2025, with potential approval as early as mid-2026[14]. - The ongoing Phase 1b trial in Celiac Disease (CeD) anticipates top-line data in Q4 2026, with a focus on mucosal healing and prevention of mucosal damage[56]. - The ongoing Phase 1b trial for ANB033 is set to initiate in Q1 2026, focusing on its efficacy in treating eosinophilic esophagitis[66]. - The Phase 1a trial of ANB033 in healthy volunteers showed no serious adverse events (SAEs) or severe adverse events (AEs), indicating favorable safety and tolerability[36]. - The Phase 2b trial for ulcerative colitis showed a favorable safety and tolerability profile, but the lack of efficacy at Week 12 led to the decision to discontinue further development in this indication[126]. Drug Mechanism and Efficacy - ANB033 demonstrated a statistically significant survival benefit in a GvHD mouse model compared to isotype control (P<0.0001) and Belatacept (P=0.003) with a 60-day study showing body weight loss was also significantly reduced (P<0.001)[32]. - ANB033 exhibited a favorable pharmacokinetic (PK) profile with a half-life of 2 to 3 weeks and full receptor occupancy maintained for over 30 days[36]. - The drug's mechanism of action targets excessive IL-15 and IL-2 production, which are key drivers of CeD inflammation[42]. - ANB033 treatment preserved villus height and crypt depth in a CeD mouse model, indicating improved histological outcomes[46]. - ANB033 significantly reduced CD122+ NK cells by over 50% with a return towards baseline within 3 months, demonstrating its potential in CeD treatment[40]. - Rosnilimab shows a best-in-disease profile in rheumatoid arthritis (RA) with a market potential of approximately $20 billion in the U.S., the first new mechanism approved since 2012[88]. - Rosnilimab demonstrated JAK-like efficacy with comparable response rates across more stringent endpoints regardless of prior therapy type, including JAKs[100]. Market Potential and Demographics - The U.S. market for patients non-responsive to a gluten-free diet is projected to be $4-5 billion, with an initial target population of approximately 1.1 million diagnosed patients[62]. - There are about 340,000 diagnosed U.S. patients with eosinophilic esophagitis (EoE), with 170,000 being biologic-eligible and around 30,000 currently treated with Dupixent[74]. - The prevalence of EoE is increasing at a compound annual growth rate (CAGR) of over 8%, with anticipated U.S. sales exceeding $5 billion by 2030[74]. - The target population for rheumatoid arthritis (RA) in the US generated approximately $10 billion in 2021, with over $1 billion in sales from Rituxan and biosimilars in the third-line treatment despite infection risks[124]. - The prevalence of RA in the US is around 1.8 million, with approximately 1 million treated with biologics and JAK inhibitors, and about 500,000 in the second-line treatment category[124]. Safety and Tolerability - Rosnilimab's safety and tolerability were favorable compared to standard of care, with strict continuation criteria preventing patients with improvement at 3 months from continuing in the trial[88]. - Serious adverse events (SAEs) were low across treatment groups, with only one ischemic stroke reported in the 100 mg group[122]. - The company observed a 90% depletion of pathogenic T cells in the Phase 2 trial for RA, indicating expected pharmacological activity[126]. - Rosnilimab demonstrated a well-tolerated safety profile with a dropout rate of less than 2% due to adverse events (AEs) over six months, with only one dropout attributed to a moderate headache[122]. Competitive Landscape - The incidence of serious adverse events (SAEs) in commercial products with black box warnings has not hindered their sales, with RA sales reaching $4.5 billion for one product[120]. - Rosnilimab's competitive landscape shows it as a best-in-class T cell depleter, outperforming competitors in pathogenic T cell depletion[116]. - The market for RA treatments remains fragmented, with no clear treatment of choice after anti-TNF failures, presenting an opportunity for new biologics[124].

Financial Performance - The company reported a net loss of RMB 43,098,780 for the fiscal year ended June 30, 2023, and a net income of RMB 13,251,753 for the fiscal year ended June 30, 2024, followed by a net loss of RMB 62,019,599 for the fiscal year ended June 30, 2025[629]. - Adjusted EBITDA for the fiscal year ended June 30, 2023 was RMB 16,687,974, while for the fiscal year ended June 30, 2024 it was RMB 16,027,851, and for the fiscal year ended June 30, 2025 it was a loss of RMB 53,875,452[629]. Credit Loss Provisions - The company accrued provisions for credit losses of approximately RMB 1.9 million, RMB 4.0 million, and RMB 12.3 million (US$1.7 million) for the fiscal years ended June 30, 2023, 2024, and 2025, respectively[616]. - The allowance for credit losses increased by RMB 8,821,129 upon the adoption of ASU 2016-13 on July 1, 2023[615]. Deferred Tax Assets - As of June 30, 2024 and 2025, the company recorded valuation allowances for deferred tax assets amounting to RMB 10.4 million and RMB 21.2 million (US$3.0 million), respectively[618]. Financing Activities - The company entered into a L1 Securities Purchase Agreement on September 23, 2024, providing for loans up to $8.0 million under three tranches[622]. - The company received net proceeds of approximately RMB 17.5 million (US$2.4 million) from convertible notes for the year ended June 30, 2025[622]. - The company has classified convertible notes as liabilities under ASC 470, estimating the fair value of the derivative liability using the Binomial Tree Model[623]. Tax Benefits - The company has not recognized any interest expense or penalty related to unrecognized tax benefits for the fiscal years ended June 30, 2024 and 2025[621]. Reserve Funds - The company’s PRC subsidiaries are required to set aside at least 10% of their after-tax profits to fund certain reserve funds until the total amount reaches 50% of their registered capital[606].

Company Structure and Operations - Global Mofy Cayman is a holding company with no significant assets or operations, conducting business in China through its subsidiaries[32]. - Global Mofy Zhejiang WFOE, incorporated on April 3, 2023, is engaged in technology development, technical services, and software development[34]. - As of the date of the report, no dividends or distributions have been made to US investors, and the company's business is primarily conducted through its subsidiaries[54]. - The company has appointed Cogency Global Inc. as its agent to receive service of process in the United States[46]. - The company has received all requisite licenses and permissions from PRC authorities to conduct its business operations, with no denials reported[66]. - The business licenses held by subsidiaries allow for a range of technology services, including development, consulting, and advertising, across various regions in China[67][68]. Financial Operations and Dividends - Current PRC regulations permit the WFOE to pay dividends to the company only out of accumulated profits, if any, determined in accordance with Chinese accounting standards[53]. - The company relies on dividends paid by its subsidiaries for working capital and cash needs, including servicing debt obligations and paying operating expenses[54]. - No dividends, distributions, or transfers have been made between Global Mofy Cayman and its subsidiaries, and no cash dividends are expected in the foreseeable future[59]. - The company’s ability to pay dividends may be restricted by debt instruments governing its subsidiaries[56]. - The company's PRC subsidiaries generate revenue primarily in Renminbi, which is not freely convertible, potentially limiting the ability to pay dividends[88]. - A withholding tax rate of up to 10% may apply to dividends payable by Chinese companies to non-PRC-resident enterprises, affecting the company's ability to distribute dividends[89]. - The company relies on dividends from its PRC subsidiaries for funding, which are subject to PRC laws that restrict payments to only after-tax profits and require statutory reserves[150][155]. Regulatory Environment - The PRC government may impose restrictions on the ability to transfer cash or assets, affecting the company's liquidity[51]. - The company must comply with PRC foreign exchange regulations for the remittance of dividends outside of China[52]. - PRC regulations require subsidiaries to set aside a minimum of 10% of net income after taxes as statutory surplus reserves until it reaches 50% of registered capital[56]. - The Holding Foreign Companies Accountable Act may impact the company's ability to complete business combinations with certain companies, particularly those with substantial operations in China[60]. - The company does not anticipate any regulatory objections to its offering from PRC authorities[68]. - The company is not currently required to obtain any other approval from Chinese authorities to list on U.S. exchanges or issue securities to foreign investors[75]. - The company must comply with new cybersecurity review measures before any public offering at a foreign stock exchange, adding potential compliance challenges[99]. - The company is subject to extensive regulation in the financial and taxation solution services industry, creating uncertainties regarding the legality of its operations[95]. Market and Competition - The company faces intense competition in the metaverse and digital entertainment industry, which could negatively impact its market share and financial performance[90]. - The company faces intense competition in the metaverse and digital entertainment industry, with significant competitors like BaseFX and SVHQ Media, which may affect market share[226]. Financial Performance - For the fiscal year ended September 30, 2025, the revenue from digital asset development reached $22.83 million, up from $20.5 million in 2024 and $11.5 million in 2023, indicating significant growth in this business line[209]. - The company incurred a net loss of $19.30 million for the fiscal year ended September 30, 2025, following a profit of $12.1 million in 2024 and $6.6 million in 2023, highlighting ongoing financial challenges[211]. - The company anticipates an increase in operating costs and expenses as it continues to grow, which may impact future profitability[212]. - The company has a limited operating history, making it difficult to predict future performance and increasing the risk of fluctuating financial results[210]. Customer and Supplier Dependency - As of September 30, 2025, one customer accounted for approximately 16% of total revenues, indicating a reliance on major customers for revenue generation[214]. - Four major suppliers accounted for approximately 19%, 14%, 11%, and 11% of total purchases for the year ended September 30, 2025, reflecting dependency on key suppliers[217]. - As of September 30, 2025, the balance due from four customers accounted for approximately 22%, 20%, 18%, and 13% of total accounts receivable, indicating potential risks in cash flow[215]. Legal and Compliance Risks - The company may face significant legal and regulatory obstacles in obtaining information for shareholder investigations or litigation outside of China[84]. - The PRC legal system's unpredictability may impede the company's ability to enforce contracts and could adversely affect operations[126]. - Enforcement of foreign judgments in China is uncertain, particularly for judgments from U.S. courts, due to the lack of reciprocal agreements[183]. - The company may face significant scrutiny and negative publicity similar to other U.S.-listed Chinese companies, which could adversely affect its operations and stock value[181]. Economic and Political Factors - The company’s operations are significantly influenced by political, economic, and social conditions in China, which could impact financial performance[128]. - Adverse changes in PRC government policies could materially affect the overall economic growth of China, reducing demand for the company's products and services[84]. - The financial and operating performance of the company may be adversely affected by general economic conditions, natural disasters, and public health crises impacting the metaverse industry[186]. - The rapid spread of COVID-19 has resulted in increased travel restrictions and business disruptions, potentially leading to financial distress for buyers and impacting revenues[187].

Financial Results - Boot Barn Holdings, Inc. announced preliminary financial results for Q3 fiscal year 2026, ending December 27, 2025[5]. - A press release detailing financial results is available as Exhibit 99.1, and a supplemental financial presentation is provided as Exhibit 99.2[10]. - The financial information provided is intended to be "furnished" and not "filed" under the Exchange Act[6]. Upcoming Events - The company will participate in the 2026 ICR Conference on January 12, 2026, where further details will be shared[7]. - The fireside chat at the ICR Conference will be webcast live, accessible via the company's investor relations website[7]. Company Information - The company is not classified as an emerging growth company under the Securities Act[4]. - The address of the company's principal executive offices is 17100 Laguna Canyon Road, Irvine, California 92618[2]. - The report was signed by James M. Watkins, Chief Financial Officer and Secretary, on January 9, 2026[14]. Investor Relations - The company reserves the right to discontinue the availability of the investor relations website at any time[9]. - The company disclaims any obligation to update or revise the information in the presentation[9].

Financial Performance - In fiscal year 2025, Hurco reported sales and service fees of $178.6 million, a decrease of $8.0 million, or 4%, compared to fiscal year 2024[15]. - The company experienced a net loss of $15.1 million, or $2.34 per diluted share, for fiscal year 2025, compared to a net loss of $16.6 million, or $2.56 per diluted share, for fiscal year 2024[15]. - Gross profit for fiscal year 2025 was $33.0 million, or 18% of sales, down from $37.7 million, or 20% of sales, in fiscal year 2024, primarily due to lower sales volume and increased costs from tariffs[200]. - Operating loss for fiscal year 2025 was $10.3 million, or 6% of sales, compared to an operating loss of $8.3 million, or 4% of sales, for fiscal year 2024[202]. - Orders for fiscal year 2025 were $171.3 million, a decrease of $27.0 million, or 14%, compared to fiscal year 2024, with a favorable currency impact of $1.8 million, or less than 1%[196]. - Backlog as of October 31, 2025, decreased to $34.3 million from $40.8 million as of October 31, 2024, primarily due to decreased customer demand[199]. - Cash and cash equivalents as of October 31, 2025, were $48.7 million, an increase from $33.3 million as of October 31, 2024, primarily due to reductions in inventories and accounts receivable[206]. - Working capital as of October 31, 2025, was $173.1 million, down from $180.8 million as of October 31, 2024, driven by decreases in inventories and accounts receivable[207]. - Selling, general, and administrative expenses for fiscal year 2025 were $43.2 million, or 24% of sales, compared to $46.0 million, or 25% of sales, in fiscal year 2024[201]. Revenue Sources - Computerized machine tools accounted for 80% of total revenues in fiscal year 2025, generating $142.3 million, down from $147.6 million in fiscal year 2024[20]. - Service parts contributed 14% to total revenues in fiscal year 2025, amounting to $25.1 million, compared to $27.6 million in fiscal year 2024[20]. - Approximately 62% of the company's revenues in fiscal year 2025 were derived from customers outside the Americas, highlighting the global market reach[93]. - In fiscal year 2025, approximately 51% of revenues were generated from customers in Europe, with 11% from the Asia Pacific region[180]. - Approximately 62% of the company's revenues in fiscal year 2025 were derived from sales to customers located outside of the Americas[114]. Market and Competitive Landscape - The demand for machine tools has fluctuated due to global economic and regulatory conditions, impacting shipment volumes in key markets[15]. - The company competes with larger machine tool producers, emphasizing proprietary software and features to enhance productivity and ease of use[96][98]. - Economic uncertainty may lead to reductions in customer capital expenditures and longer sales cycles, negatively impacting the company's business[111]. - The company competes with larger firms that have greater financial resources, making it challenging to maintain competitiveness[120]. Strategic Initiatives - The company has made five acquisitions since 2013, enhancing product offerings and improving machine tool accuracy and precision[14]. - Hurco's strategy includes market expansion to reach more customers globally, with a focus on product diversity and penetration across various industries[14]. - The company actively seeks acquisitions to expand its product offerings, which involve risks such as integration difficulties and diversion of management's attention[130]. - The company has introduced non-Hurco branded products to diversify its offerings and reduce the impact of geographic cyclicality in the machine tool market[86]. Product Development and Innovation - The DCX series offers four sizes of machining centers designed for large parts and molds, with 2- and 3-meter models featuring two spindle sizes and 3- and 4-meter models available as five-axis machines[38]. - The TM product line includes 2-axis turning models in four sizes, with the TM-M series enhancing productivity through motorized tooling, allowing secondary operations while parts are held in the chuck[39]. - The next generation VC 500 5-axis machine is set to launch in early 2026, featuring improved automation integration and ergonomics, aligning with market needs[42]. - The Milltronics INSPIRE+ control console, launched in 2024, enhances cutting precision and surface finish, compatible with G & M Code programs[43]. - The new TRL toolroom flatbed lathes and X5 five-axis integrated machines were introduced in fiscal year 2024, expanding Milltronics' product offerings[53]. - The Takumi UVC600 five-axis machine features a 600mm cantilever table and a 15,000rpm direct drive spindle for high accuracy and complex parts production[66]. - Software options for Hurco computerized machine tools include Advanced Verification Graphics and Solid Model Import, enhancing programming efficiency and accuracy[69]. - The VM product line consists of attractively-priced vertical machining centers available in four sizes, designed for job shops and general machining applications[46]. - The HMX Series high-speed horizontal machining centers are capable of up to 1G acceleration and include twin pallets for maximizing cutting time[64]. - The DXF Transfer software option enhances operator productivity by eliminating manual data entry, allowing direct transfer of AutoCAD® drawing files into the control software[71]. - UltiMonitor, a web-based tool, enables customers to monitor and receive notifications about their Hurco machines from any internet-accessible location, improving operational efficiency[72]. - The Tool and Material Library option streamlines tool data management, saving time and preventing tool crash conditions by storing information centrally[74]. - Simultaneous Five-Axis Contouring software allows for concurrent motion on all axes, increasing productivity and enabling complex geometries with a single setup[79]. Operational Risks and Challenges - The company faces significant risks due to fluctuations in global economic conditions, which have adversely affected its results of operations and financial condition[110]. - Tariffs imposed by the U.S. government on foreign goods have increased operating costs and could require significant costs to transition to alternative manufacturers or suppliers[112]. - The company is exposed to exchange rate fluctuations, as approximately 62% of revenues are invoiced in foreign currencies, primarily the Euro, Pound Sterling, Chinese Yuan, and Indian Rupee[119]. - The company relies on its wholly owned subsidiaries and third-party suppliers for production, and any unplanned interruptions could materially affect its business and financial condition[127]. - The company must comply with complex foreign and U.S. laws, and violations could result in significant penalties and adversely affect its operations[116]. - Fluctuations in the prices of raw materials, especially steel and energy, could adversely affect the company's sales, costs, and profitability[128]. - The company faces risks related to mergers and acquisitions, including potential failure to integrate acquired companies, which could adversely affect business and financial condition[131]. - Compliance with data privacy and security laws is critical, with potential penalties for violations that could significantly impact operating results[135]. - Cybersecurity threats are a significant risk, and while the company has not experienced material incidents, ongoing risks could affect business strategy and financial condition[157]. - The company has implemented a comprehensive cybersecurity strategy, including advanced safeguards and an incident response plan to mitigate risks[155]. - Public health emergencies, such as pandemics, have disrupted operations and could continue to adversely affect business and financial results[139]. - The company continues to monitor and assess the impact of evolving data protection laws in various jurisdictions, which may impose substantial compliance costs[134]. Human Resources and Corporate Structure - As of October 31, 2025, the company employed approximately 651 full-time employees, with 30% in the Americas and 70% in other global regions, focusing on advanced manufacturing[101]. - The company’s executive team includes experienced professionals with backgrounds in technology and finance, contributing to effective risk management[159]. - The company has a strong focus on cybersecurity risk management, overseen by the Audit Committee and senior management[159]. - The company has a history of profitability and a strong balance sheet, which it relies on to navigate market cyclicality[181]. - The company’s facilities are well maintained and adequate for current and future needs, with leases expiring between January 2026 and July 2032[160]. - The company sells products through approximately 160 independent agents and distributors globally, with a significant presence in major machine tool consuming markets[183]. - The company’s corporate headquarters in Indianapolis, Indiana, spans 165,000 square feet, while its manufacturing facility in Taichung, Taiwan, covers 370,100 square feet[160].

Financial Performance - Consolidated revenue for the quarter ended November 30, 2025, was $64.0 million, a decrease of 7.5% from $69.1 million in the same quarter of fiscal 2025[62] - Gross profit for the first quarter of fiscal 2026 was $48.4 million, down from $52.7 million in the prior year, resulting in a gross margin of 75.5% compared to 76.3%[62] - Enterprise Division revenues for the first quarter of fiscal 2026 totaled $47.5 million, a decline of 7.9% from $51.6 million in the first quarter of fiscal 2025[63] - Education Division revenues were $16.1 million, down from $16.5 million in the prior year, primarily due to reduced classroom and training materials sales[63] - Consolidated subscription and subscription services revenues for the first quarter of fiscal 2026 were $52.0 million, compared to $55.8 million in the prior year[63] - Net loss for the first quarter of fiscal 2026 was $(3.3) million, or $(0.27) per share, compared to net income of $1.2 million, or $0.09 per diluted share, in the first quarter of fiscal 2025[66] - Adjusted EBITDA for the first quarter of fiscal 2026 totaled $3.7 million, down from $7.7 million in the prior year[66] Segment Performance - North America segment revenue was $36.3 million, a decrease of 9.7% from $40.1 million in the prior year, impacted by lower invoiced amounts and canceled government contracts[65] - International segment revenue was $11.2 million, a decrease of 2.1% from $11.4 million in the prior year, primarily due to lower revenue from the China office[69] - Education Division revenue for Q1 FY2026 decreased by 2% to $16.1 million compared to $16.5 million in Q1 FY2025, primarily due to lower sales of classroom and training materials[72] - Gross profit for the Education Division declined to $9.9 million, with a gross margin of 61.6%, down from 63.2% in the prior year, attributed to increased fixed costs and lower revenue[73] Expenses and Cash Flow - SG&A expenses increased to $10.8 million, representing 67.4% of sales, due to higher associate expenses and changes in compensation plans[74] - Cash provided by operating activities was $0.1 million, a significant decrease from $14.1 million in the prior year, mainly due to unfavorable changes in working capital[84] - Cash used for investing activities totaled $3.8 million, with $2.0 million allocated to the development of offerings and $1.7 million for property and equipment[86][88] Liquidity and Capital Expenditures - The company had $80 million in available liquidity as of November 30, 2025, consisting of $17.5 million in cash and a $62.5 million undrawn revolving credit facility[80] - The company anticipates capital spending for curriculum development to be between $8 million and $10 million in FY2026[87] Tax and Interest Rates - The effective tax benefit rate for Q1 FY2026 was 9.4%, significantly lower than the 25.6% rate in Q1 FY2025, due to a decrease in non-deductible executive compensation[78] - The effective interest rate on the 2023 Credit Agreement was 5.5% as of November 30, 2025[105] - There were no outstanding borrowings under the 2023 Credit Agreement as of November 30, 2025, indicating no material impact from interest rate changes on interest expense and cash flows[105] - The company has fixed long-term obligations primarily from the purchase of Strive Talent, Inc., which influences overall interest rate sensitivity[105] - The company did not utilize any foreign currency or interest rate derivative instruments during the quarter ended November 30, 2025[106] Future Outlook - Forward-looking statements include expectations about future revenue levels and financial results, particularly for fiscal 2026[101] - Anticipated increases in add-on subscription services revenue and delivered training and coaching days are part of the company's future outlook[101] - The company is focused on hiring sales professionals to support its growth strategy[101] - The company acknowledges risks such as cybersecurity, macroeconomic factors, and competition that may affect future performance[102] - The market price of the company's common stock has been volatile, influenced by quarter-to-quarter variations in revenues and earnings[103] - The company does not undertake any responsibility to update forward-looking statements except as required by law[104]

Share Capital and Shareholder Rights - The authorized share capital of GLOBAL MOFY AI LIMITED is US$1,020,000.00, divided into 30,000,000,000 Class A Shares and 4,000,000,000 Class B Shares, each with a par value of US$0.00003[3]. - Each Class A Share entitles the holder to one vote, while each Class B Share entitles the holder to twenty votes on all matters at general meetings[18]. - Class B Shares do not confer any rights to receive dividends, whereas Class A Shares do[18]. - The Company has the power to issue shares with special rights or restrictions as determined by the Directors[7]. - The liability of each Shareholder is limited to the amount unpaid on their shares[6]. - Shareholders holding at least 30% of voting rights can requisition a general meeting, ensuring significant shareholder influence in Company decisions[54]. - The Company may fix a record date for determining shareholders entitled to dividends, ensuring clarity in dividend distribution[51]. Share Management and Financial Security - The Company may purchase its own shares, including redeemable shares, on terms determined by the Directors[20]. - The Company has a first priority lien on every partly paid or unpaid share for all moneys called or payable, ensuring financial security for the Company[22]. - The Directors may sell shares on which the Company has a lien after a 14-day notice period, allowing for effective management of unpaid shares[23]. - If a call remains unpaid, interest will accrue at a rate of 10% per annum until payment is made, incentivizing timely payments from shareholders[28]. - The Company may forfeit shares if payment requirements are not met after a specified notice period, allowing for the recovery of unpaid amounts[34]. - The Directors have the authority to make arrangements regarding the payment of calls on partly paid shares, providing flexibility in financial management[30]. - The Company may increase its share capital through new shares as per Ordinary Resolution, allowing for potential growth and expansion[48]. Meetings and Resolutions - A general meeting requires at least five clear days' notice to shareholders, specifying the meeting's details[44]. - A quorum for a general meeting is one or more shareholders holding at least one-third of the voting power of all outstanding shares[58]. - If a quorum is not present within half an hour, the meeting will be adjourned to the same time and place seven days later[59]. - Shareholders may participate in meetings via telephone or similar communication equipment, which counts as presence[60]. - Resolutions at general meetings are typically decided by a show of hands unless a poll is demanded by the chairman or shareholders holding at least 30% of the voting rights[64]. - A written resolution can be passed without a meeting if all shareholders entitled to vote are notified and agree[52]. Directors and Management - Directors may appoint additional directors at any time, and the company can fix the maximum and minimum number of directors by ordinary resolution[79]. - Directors are entitled to remuneration as determined by the board, with no shareholding qualification required unless specified[81]. - The company may validate prior acts of directors that breach their duties through a special resolution[86]. - Directors have the power to borrow money and mortgage the company's property as needed[87]. - The Directors have the authority to appoint various officers, including a President and Vice-Presidents, to manage the Company as deemed necessary[88]. - The Company may establish local or divisional boards for management purposes, with Directors having the power to delegate authority to these boards[97]. - The Directors are responsible for maintaining minutes of meetings, including appointments and resolutions made[107]. - A quorum for Directors' meetings is two if there are two or more Directors, and one if there is only one Director[101]. - Directors may participate in meetings via telephone or similar communication equipment, which counts as presence at the meeting[100]. - The Directors may delegate powers to committees, which must include a majority of Independent Directors as required by listing rules[90]. Dividends and Financial Management - Directors may declare dividends from legally available funds, including interim dividends, subject to the approval of an Ordinary Resolution[119]. - Dividends may be paid in cash or in kind, and will be declared based on the amount paid on shares or their par value if unpaid[123][124]. - The Company may set aside reserves from available funds before declaring dividends for contingencies or equalizing dividends[121]. - The Company may capitalize any part of its profits not required for paying preferential dividends or any sum standing to the credit of the share premium account[77]. - The amount resolved to be capitalized must be appropriated to Shareholders in the same proportions as if it had been distributed by way of dividend[135]. - Any dividend that remains unclaimed for a period of six years shall be forfeited to the Company[127]. Accounting and Auditing - The Company may appoint Auditors, but is not required to do so, and the accounts shall be audited as determined by the Company[131]. - The Directors shall establish a share premium account and carry to its credit a sum equal to the premium paid on the issue of any share[132]. - The books of account relating to the Company's affairs shall be kept at the registered office or other places determined by the Directors[128]. Legal and Administrative Provisions - The Company may execute deeds without a seal by the signature of a Director or Secretary, as authorized by the Directors[118]. - Any notice or document served by post shall be deemed to have been served five days after posting[138]. - The Directors have the authority to present a petition for the winding up of the Company without the sanction of a resolution passed at a general meeting[146].